Mackenzie Financial
VYNE icon

Mackenzie Financial’s VYNE Therapeutics VYNE Stock Holding History

Mackenzie Financial’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,496
Closed -$20.2K – 1620
2022
Q4 		$20.2K Hold
7,496
– – ﹤0.01% 1398
2022
Q3 		$30K Buy
7,496
+3,871
+107% +$24.8K ﹤0.01% 1392
2022
Q2 		$25K Hold
3,625
– – ﹤0.01% 1431
2022
Q1 		$42K Buy
+3,625
New +$43.1K ﹤0.01% 1376

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Mackenzie Financial's VYNE Position: Q1 2023 in Review

Mackenzie Financial sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 7,496 shares — an estimated $20.2K sold.

Mackenzie Financial first reported a position in VYNE in Q1 2022 and held it in 4 quarters. The position peaked at $42K in Q1 2022. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

  • Mackenzie Financial reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Mackenzie Financial sold 7,496 VYNE Therapeutics shares in Q1 2023, an estimated $20.2K.
  • Mackenzie Financial first reported a position in VYNE Therapeutics in Q1 2022 and held it in 4 quarters.
  • Mackenzie Financial's VYNE Therapeutics position peaked at $42K in Q1 2022.
  • 23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on Mackenzie Financial's 13F filing for Q1 2023, filed 24 Apr 2023.